SCHEMBL23926985

SCHEMBL23926985

Cc1ccc(Oc2ccc([N+](=O)[O-])cn2)cc1Cl

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSPB1 P04792 2/20 0.59
MEN1 O00255 8/20 0.55
KMT2A Q03164 8/20 0.55
MAPT P10636 4/20 0.54
NPSR1 Q6W5P4 1/20 0.54
GAA P10253 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
ALDH1A1 P00352 3/20 0.52
LMNA P02545 3/20 0.52
HTT P42858 3/20 0.52
MAPK1 P28482 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
PPARG P37231 1/20 0.50
KDM4E B2RXH2 1/20 0.48
POLB P06746 1/20 0.48
HPGD P15428 2/20 0.46
RAB9A P51151 2/20 0.44
PABPC1 P11940 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30079719 1.00 HSPB1 (0.59) HSPB1MEN1KMT2AMAPTNPSR1
SCHEMBL11162289 0.88 HSPB1 (0.63) HSPB1MEN1KMT2AMAPTNPSR1
SCHEMBL1498294 0.84 HSPB1 (0.67) HSPB1MEN1KMT2AMAPTNPSR1
SCHEMBL1983457 0.83 HSPB1 (0.58) HSPB1MEN1KMT2AMAPTNPSR1
SCHEMBL30079826 0.83 HSPB1 (0.58) HSPB1MEN1KMT2AMAPTNPSR1
SCHEMBL6208366 0.83 HSPB1 (0.60) HSPB1MEN1KMT2AMAPTNPSR1
SCHEMBL11782945 0.82 MEN1 (0.55) HSPB1MEN1KMT2AMAPTNPSR1
SCHEMBL22529936 0.82 HSPB1 (0.59) HSPB1MEN1KMT2AMAPTNPSR1
SCHEMBL2450899 0.82 HSPB1 (0.59) HSPB1MEN1KMT2AMAPTNPSR1
SCHEMBL29351818 0.82 HSPB1 (0.59) HSPB1MEN1KMT2AMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230124087-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 US disclosed
EP-4139306-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2023-03-01 EP disclosed
CN-115380032-A KV3 enhancers for the treatment of cognitive disorders 豪夫迈·罗氏有限公司 2022-11-22 CN disclosed
WO-2021214090-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2021-10-28 WO disclosed
EP-3901152-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2021-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230124087-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS KCNN3, KCNA4, KCNA3 HSPB1 2043/4885MEN1 2507/4885KMT2A 411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.